Loading...
Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/ https://ncbi.nlm.nih.gov/pubmed/32630154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|